Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma

Mhawech‐Fauceglia, Paulette; Wang, Dan; Syriac, Susanna; Godoy, Heidi; duPont, Nefertiti C.; Song, Liu‐Dong; Odunsi, Kunle

doi:10.1016/j.ygyno.2011.09.037

Cited by 26 publications

(22 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings of high levels of SNCG expression in ovarian cancer were consistent with SNCG expression in multiple cancer types, including breast, liver, prostate, and colon cancer [14, 21, 24, 25]. However, unlike breast [12] and endometrial cancers [19] in which high SNCG expression has been correlated with adverse clinical outcomes, our study found no correlation between high SNCG expression and clinical outcomes.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundSynuclein gamma (SNCG) expression is associated with advanced disease and chemoresistance in multiple solid tumors. Our goal was to determine if SNCG protein expression in ovarian cancer was correlated with clinicopathologic variables and patient outcomes.MethodsTissue microarrays from primary tumors of 357 ovarian, fallopian tube, and primary peritoneal cancer patients, who underwent primary surgery at Roswell Park Cancer Institute between 1995 and 2007, were immunohistochemically stained for SNCG. A pathologist blinded to patient data scored tumors as positive if ≥10 % of the sample stained for SNCG. Medical records were reviewed for clinicopathologic and demographic variables. Between the positive and negative groups, Wilcoxon rank-sum test was used to compare the median ages and Fisher’s exact test was used to compare groups in categorical variables. Cox proportional hazard models examined associations between SNCG and overall and progression-free survival.ResultsThe median follow-up was 36 months, median overall survival was 39 months, and median progression-free survival was 18 months. SNCG presence was associated with clinical variables of serous histology, grade 3 disease, suboptimal debulking, ascites at surgery, FIGO stage III-IV cancer, or initial CA-125 level >485. There was no significant difference in overall survival (HR 1.06 95 % CI 0.81–1.39 P 0.69) or progression-free survival (HR 1.16 95 % CI 0.89–1.50 P 0.28) for patients with or without SNCG expression.ConclusionsSNCG expression in ovarian cancer is frequent in patients with high-risk features, but it does not correlate with chemotherapy response, overall survival, or progression-free survival.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-016-0281-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 82%

“…Tissues were prepared for analysis, as previously described by Mhawech-Fauceglia et al [19]. Briefly, high-density TMA blocks were sectioned in 4 μm thickness followed by deparaffinization with xylene, then washed with ethanol.…”

Section: Methodsmentioning

confidence: 99%

Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…And multivariable analyses showed that γ-synuclein was correlated with OS of the patients, which is the same as previous observations of an association between γ-synuclein expression and OS in uterine papillary serous carcinoma15 and is the same with Mhawech-Fauceglia,16 who considered that γ-synuclein protein expression is associated with poor outcome in endometrial adenocarcinoma and γ-synuclein expression as an independent prognostic factor in endometrial adenocarcinoma. Probably, due to the small number of the patients who got a recurrence (only 6 of 60 patients formed disease recurrence), when analysed the impact of γ-synuclein expression and clinicopathological features to the prognosis of DFS, no significant difference was found (data not shown), in contrast to previous studies 9 14.…”

Section: Discussionsupporting

confidence: 88%

An exploratory analysis of γ-synuclein expression in endometrioid endometrial cancer

et al. 2012

View full text Add to dashboard Cite

ObjectiveThis study aims to investigate the expression of γ-synuclein in endometrioid endometrial carcinoma and assess if the γ-synuclein expression correlates with the aggression of the tumour and its prognostic value in endometrioid endometrial carcinoma.DesignThis retrospective study evaluated (60) specimens of the primary untreated endometrioid endometrial carcinoma and (12) normal endometrium tissues, and the expression of γ-synuclein was checked by immunohistochemistry. The correlation between γ-synuclein expression and the clinicopathological features of patients with endometrioid endometrial carcinoma was analysed, and SPSS V.13.0 software was used for statistical analysis.ResultsThe expression of γ-synuclein was positive in 48.3% (29/60) endometrioid endometrial carcinomas compared with the control group, and the difference was significant (p=0.001). The expression level of γ-synuclein in endometrioid endometrial carcinoma was closely associated with FIGO (International Federation of Gynecology and Obstetrics) stages, the depth of myometrial invasion and lymph nodes metastases (p<0.05), but not correlated with the histopathological grades, the patient's age and the expression of ER (estrogen receptor) and PR (progesterone receptor) (p>0.05). In univariate and multivariate analyses, the γ-synuclein expression was significantly associated with a shorter overall survival (95% CI 1.429 to 101.892, p=0.020).ConclusionsThis study suggests that the expression of γ-synuclein is expected to be a useful marker for endometrioid endometrial carcinoma invasion, metastasis and prognosis in endometrioid endometrial carcinoma.

show abstract

“…Although statistical significance was not reached because of a limited sample size, a trend toward an association of SNCG with decreased progression‐free survival was evident. In a larger study evaluating 279 endometrial carcinomas with various histologies, of which 46 were USC, SNCG expression was positive in tumors from patients who had worse overall outcomes, especially those with clear cell, serous, and carcinosarcoma histologies . These data strongly suggest that SNCG may be a prognostic biomarker for USC.…”

Section: Introductionmentioning

confidence: 89%

“…It has been demonstrated that synuclein-c (SNCG) is overexpressed in USC. [4][5][6] SNCG is a member of the synuclein family of proteins, which are small, soluble, highly conserved neuronal proteins implicated in both neurodegenerative diseases and cancer. SNCG overexpression occurs in multiple cancers, including colon, gastric, pancreatic, ovarian, and lung cancers.…”

Section: Introductionmentioning

confidence: 99%

Synuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study

Winder¹,

Maniar²,

Wei³

et al. 2016

Cancer

View full text Add to dashboard Cite

Background Synuclein-γ (SNCG) is highly expressed in advanced solid tumors, including in uterine serous carcinoma (USC). The goal was to determine if SNCG protein was associated with survival and clinical covariates using the largest existing collection of USC from the Gynecologic Oncology Group (GOG-8023). Methods High-density tissue microarrays (TMAs) of tumor tissues of 313 patients with USC were stained by immunohistochemistry (IHC) for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu. Association of SNCG and other tumor markers with overall and progression-free survival was assessed using Logrank tests and Cox proportional hazards models including adjustment for age, race, and stage. Results Overall survival at 5 years was 46% for high and 62% for low SNCG expression groups (logrank p=0.021, hazard ratio [HR]=1.31, 95% confidence interval [CI]= 0.91-1.9 in adjusted Cox model). Progression free survival at 5 years was worse for high SNCG at 40% compared to 56% for low SNCG (logrank p=0.0081, [HR]=1.36, 95% [CI]= 0.96-1.92 in adjusted Cox model). High levels of both p53 and p16 were significantly associated with worse overall survival (p53: [HR]=4.20, 95% [CI]=1.54-11.45; p16: [HR]= 1.95, 95% [CI]=1.01-3.75) and progression-free survival (p53: [HR]= 2.16, 95% [CI]=1.09-4.27; p16: ([HR]= 1.53, 95% [CI]=0.87-2.69) compared to low levels. Conclusions This is the largest collection of USC cases to date demonstrating that SNCG was associated with poor survival in USC in univariate analyses. SNCG does not predict survival outcome independently of p53 and p16 in models that jointly consider multiple markers.

show abstract

Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma

Cited by 26 publications

References 22 publications

Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease

Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease

An exploratory analysis of γ-synuclein expression in endometrioid endometrial cancer

Synuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study

Contact Info

Product

Resources

About